New Research on SINOVAC’s COVID-19 Vaccine Shows Third Dose More Effective Against COVID-19, Including the Delta Variant
September 09 2021 - 6:00AM
Business Wire
Study findings demonstrate that a booster dose
of inactivated COVID-19 vaccine produces a highly sifted, humoral
immune response via a sustained evolution of antibodies, able to
effectively neutralize SARS-CoV-2 variants of concern.
SINOVAC Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”),
a leading provider of biopharmaceutical products in China,
announced a paper, titled “A third dose of inactivated vaccine
augments the potency, breadth, and duration of anamnestic responses
against SARS-CoV-2,” is available on medRxiv. The findings suggest
a third dose of CoronaVac® can induce a better neutralization
breadth to variants of concern (“VOCs”), including the Delta
variant, a rapid immunological memory response, and a long-lasting
humoral response. Having a third dose of inactivated COVID-19
vaccine is more effective for COVID-19 prevention.
This study includes an in-depth exploration of the immunogenic
profiles of antibodies from three and two-dose CoronaVac®
recipients and convalescents. The findings indicate that three-dose
vaccinees demonstrated better neutralization breadth to VOCs,
expeditious recall, and long-lasting humoral immune response.
Analysis of 171 complex structures of neutralizing antibodies
identified structure-activity correlation and revealed ultrapotent,
VOCs-resistant, and broad-spectrum patches.
As part of this study, researchers also constructed immunogenic
and mutational heat maps, which revealed a direct relationship
between “hot” immunogenic sites and areas with high mutation
frequencies. Prolonged and repeated antigen stimulation can induce
ongoing antibody somatic mutation, memory B cell clonal turnover,
and antigen composition changes in B cell repertoire, which result
in the development of monoclonal antibodies with enhanced
neutralizing potency and breadth.
The above research provides a theoretical basis for a third dose
of inactivated COVID-19 vaccine.
About SINOVAC
SINOVAC Biotech Ltd. is a China-based biopharmaceutical company
that focuses on the research, development, manufacturing and
commercialization of vaccines that protect against human infectious
diseases. SINOVAC's product portfolio includes vaccines against
COVID-19, enterovirus71 (EV71), hepatitis A and B, seasonal
influenza, 23-Valent pneumococcal polysaccharide (“PPV”), H5N1
pandemic influenza (avian flu), H1N1 influenza (swine flu),
varicella, mumps and Poliomyelitis. SINOVAC’s COVID-19 vaccine,
CoronaVac®, has been granted emergency use approval or conditional
marketing authorization by over 50 countries or regions worldwide.
Healive®, the hepatitis A vaccine manufactured by the Company, has
passed the assessment under WHO prequalification procedures in
2017. The EV71 vaccine, an innovative vaccine developed by SINOVAC
against hand foot and mouth disease caused by EV71, was
commercialized in China in 2016. In 2009, SINOVAC was the first
company worldwide to receive approval for its H1N1 influenza
vaccine, which it has supplied to the Chinese Government's
vaccination campaign and stockpiling program. The Company is also
the only supplier of the H5N1 pandemic influenza vaccine to the
government stockpiling program. In 2021, SINOVAC’s Sabin-strain
inactivated polio vaccine has approved for registration. The
Company is developing several new products including combined
vaccines. SINOVAC primarily sells its vaccines in China, while also
exploring growth opportunities in international markets. The
Company is seeking market authorization of its products in over 30
countries outside of China. For more information, please see the
Company’s website at www.sinovac.com.
Safe Harbor Statement
This press release may include certain statements that are not
descriptions of historical facts, but are forward-looking
statements. These statements are made under the “safe harbor”
provisions of the U.S. Private Securities Litigation Reform Act of
1995. These forward-looking statements can be identified by
terminology such as “will,” “expects,” “anticipates,” “future,”
“intends,” “plans,” “believes,” “estimates” and similar statements.
Forward-looking statements involve risks, uncertainties and other
factors that could cause actual results to differ materially from
those contained in any such statements. In particular, the outcome
of any litigation is uncertain, and the Company cannot predict the
potential results of the litigation it filed or filed against it by
others. Additionally, the triggering of a shareholder rights plan
is nearly unprecedented, and the Company cannot predict the impact
on the Company or its stock price as a result of the trigger of the
rights plan.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210909005437/en/
Sinovac Biotech Ltd. Helen Yang Tel: +86-10-8279-9871 or
+86-10-5693-1897 Fax: +86-10-6296-6910 Email: ir@sinovac.com
ICR Inc. Bill Zima U.S.: 1-646-308-1707 Email:
william.zima@icrinc.com
Sinovac Biotech (NASDAQ:SVA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sinovac Biotech (NASDAQ:SVA)
Historical Stock Chart
From Apr 2023 to Apr 2024